This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Goldstein, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Goldstein, B. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2005, p. 4795-4797, Vol. 49, No. 11
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.11.4795-4797.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis

M. A. Pfaller,1,3* D. J. Diekema,1,2 L. Boyken,1 S. A. Messer,1 S. Tendolkar,1 R. J. Hollis,1 and B. P. Goldstein4

Departments of Pathology,1 Medicine,2 Epidemiology, Roy J. and Lucille A. Carver College of Medicine, College of Public Health, University of Iowa, Iowa City, Iowa 52242,3 Vicuron Pharmaceuticals Inc., King of Prussia, Pennsylvania 194064

Received 16 May 2005/ Returned for modification 8 June 2005/ Accepted 29 August 2005


arrow
ABSTRACT
 
In a phase 2 open-label, dose-ranging study in patients with candidemia, anidulafungin was effective in eradicating Candida albicans and other species of Candida. The anidulafungin MIC distribution showed that Candida albicans and C. glabrata were the most susceptible species and C. parapsilosis was the least susceptible species.


arrow
TEXT
 
Anidulafungin is a semisynthetic echinocandin under development for the treatment of fungal infections, including invasive candidiasis. The most common species associated with candidemia remains Candida albicans (50 to 60% of cases), but non-C. albicans species, especially C. glabrata (approximately 20% of cases) followed by C. parapsilosis, C. tropicalis, and C. krusei, have emerged as significant pathogens (5, 7). The toxicity of polyenes and resistance to azoles have led to increased interest in alternative classes of antifungal agents, particularly those which target fungus-specific processes and promise to be well tolerated. Anidulafungin, like other echinocandins, targets the fungal cell wall, is fungicidal for all species of Candida, and is active against strains resistant to amphotericin B and azoles (4, 11, 13, 15, 17).

Anidulafungin was recently evaluated in an open-label, noncomparative, dose-ranging, phase 2 study in 123 adults with invasive candidiasis (8). We now report on the Candida isolates from the study, their susceptibilities, and the pathogen eradication rates obtained for different species and dosage regimens.

Study design. Adult patients with candidemia (94% of total) and/or candidiasis at another normally sterile site (seven patients) were randomized to receive 50, 75, or 100 mg of intravenous anidulafungin daily (after a loading dose consisting of twice the daily dose on day 1) until 2 weeks after clinical cure or improvement (and eradication or presumed eradication of Candida) or treatment failure but not to exceed 42 days of treatment. A follow-up evaluation occurred 2 weeks after the end of therapy or at the time of treatment failure. In each group, 40 patients received anidulafungin, and a total of 68 patients (respectively, 18, 26, and 24 in the three groups) completed the study and were evaluable at follow-up.

The modified intent-to-treat population consisted of those patients who received at least one dose of anidulafungin and had Candida isolated at baseline (i.e., immediately preceding start of treatment). Patients with fungal infections other than those with Candida or with yeast fungemia not identified to species level were not included in this population. The primary endpoint of the study was response at follow-up in the evaluable population. This was the subset of the modified intent-to-treat patients who either completed the study with a sufficient length of treatment (≥10 doses) and no protocol violations that affected assessment of efficacy or were identified as failures by the investigator after at least 5 doses of anidulafungin.

Candida isolates. Blood was cultured at baseline (before treatment), during treatment (on days 1, 2, and 6 and then once weekly), at the follow-up visit, and as clinically indicated. Cultures of other normally sterile sites were performed as clinically indicated. The majority of patients (94%) had candidemia, and only 10% had Candida identified at another normally sterile site (five patients had both blood and tissue sites positive). Isolates were presumptively identified at the local laboratories (30 participating centers in the United States) and then sent to a reference laboratory at the University of Iowa (Iowa City) for definitive identification to species level and MIC determinations by the Clinical and Laboratory Standards Institute (formerly NCCLS) broth microdilution method (12). All baseline isolates of Candida spp. (127 isolates) from all patients who received anidulafungin were tested against anidulafungin and four comparator antifungal agents: fluconazole, voriconazole, amphotericin B, and caspofungin. The MIC endpoint utilized for anidulafungin and caspofungin in this study was complete inhibition (MIC0) after 48 h of incubation, a conservative parameter, which was considered standard at the time that the study was initiated (2). The MIC endpoint criteria for fluconazole, voriconazole, and amphotericin B were those recommended by the Clinical and Laboratory Standards Institute (12).

The distribution of baseline pathogens among species in the three treatment groups and the anidulafungin MIC statistics are shown in Table 1. Although this was a relatively small study, the frequency of isolation of different Candida species was similar to what has been reported in the literature for bloodstream infections (5, 7). The overall median anidulafungin MIC was 0.25 µg/ml. As seen with other echinocandins (6, 9, 10, 13), most MICs above 1 µg/ml were attributable to C. parapsilosis. MIC ranges and MICs at which 90% of the isolates tested are inhibited (MIC90s) similar to those determined in this clinical trial have been reported from other in vitro studies when the same methodology has been used (1, 3, 6, 9, 13, 14, 19). MIC90s generated with the more recently adopted prominent inhibition endpoint tend to be 1 to 2 dilutions lower, as seen in a recent survey of Candida bloodstream isolates (Table 1) (10).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Distribution of baseline Candida species and anidulafungin MICs

MICs were also determined for comparators, including azoles, amphotericin B, and caspofungin (data not shown). Considering baseline isolates from all patients, all 4 C. krusei isolates, 16 of the 31 C. glabrata isolates, and 2 of 59 C. albicans isolates were nonsusceptible to fluconazole (MIC, >8 µg/ml). Additionally, one isolate of C. tropicalis had a caspofungin MIC of 16 µg/ml (2 µg/ml for anidulafungin); this strain was twice reisolated early in therapy but was then eradicated.

Eradication rates of Candida spp. in the 68 evaluable patients showed a dose-related trend, with 74, 85, and 89% success at 50, 75, and 100 mg/day of anidulafungin, respectively (Table 2). Among all three treatment arms, 61 of 73 baseline pathogens were eradicated or presumed to be eradicated (follow-up culture was unavailable for a patient with a clinical evaluation of success), and the majority of these (49 isolates) were documented by negative blood cultures. Eradication rates for the more commonly isolated individual species were comparable to the eradication rate for all species combined (Table 2). The patients' clinical and global response rates were similar to the eradication rates (8). Success was not related to the anidulafungin MIC for the isolates, and in particular, six of seven C. parapsilosis isolates, for which anidulafungin MICs were 4 to 8 µg/ml, were eradicated among the three study arms (Table 3). This lack of in vitro-in vivo correlation is not unusual in clinical trials of a new antifungal agent, largely due to the fact that the overall number of isolates tested, and specifically the number with true resistance to the new agent, is usually too small to demonstrate such a correlation (18). These results should be approached with caution, since evidence is pointing to the fact that the reading endpoints chosen for this study may not be optimal (16). Results and correlation with clinical response may be different if the 24-h prominent growth reduction endpoint is used (10, 16).


View this table:
[in this window]
[in a new window]
  		TABLE 2. Eradication rates of the more frequently isolated Candida species


View this table:
[in this window]
[in a new window]
  		TABLE 3. Response to therapy by MIC and daily dose of anidulafungin for baseline isolates of Candida spp.

In conclusion, in a phase 2 open-label, noncomparative, dose-ranging study, anidulafungin was effective in eradicating Candida spp. from the bloodstream and from other normally sterile sites. The eradication rate was high for different frequently encountered species including C. parapsilosis. A trend toward dose dependence was observed, and the highest daily dose tested (100 mg/day) is being evaluated in a phase 3 comparative study.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: michael-pfaller{at}uiowa.edu. Back


arrow
REFERENCES
 
    1
  1. Arevalo, M. P., A. J. Carrillo-Munoz, J. Salgado, D. Cardenes, S. Brio, G. Quindos, and A. Espinel-Ingroff. 2003. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method. J. Antimicrob. Chemother. 51:163-166.[Abstract/Free Full Text]
    2. 2
  2. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.[Abstract/Free Full Text]
    3. 3
  3. Chavez, M., S. Bernal, A. Valverde, M. J. Gutierrez, G. Quindos, and E. M. Mazuelos. 1999. In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J. Antimicrob. Chemother. 44:697-700.[Abstract/Free Full Text]
    4. 4
  4. Cuenca-Estrella, M., E. Mellado, T. M. Diaz-Guerra, A. Monzon, and J. L. Rodriguez-Tudela. 2000. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B. J. Antimicrob. Chemother. 46:475-477.[Abstract/Free Full Text]
    5. 5
  5. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J. Clin. Microbiol. 40:1298-1302.[Abstract/Free Full Text]
    6. 6
  6. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.[Abstract/Free Full Text]
    7. 7
  7. Gudlaugsson, O., S. Gillespie, K. Lee, B. J. Vande, J. Hu, S. Messer, L. Herwaldt, M. Pfaller, and D. Diekema. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.[CrossRef][Medline]
    8. 8
  8. Krause, D. S., J. Reinhardt, J. A. Vazquez, A. Reboli, B. P. Goldstein, M. Wible, and T. Henkel. 2004. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob. Agents Chemother. 48:2021-2024.[Abstract/Free Full Text]
    9. 9
  9. Marco, F., M. A. Pfaller, S. A. Messer, and, R. N. Jones. 1998. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 32:33-37.[CrossRef][Medline]
    10. 10
  10. Messer, S. A., J. T. Kirby, H. S. Sader, T. R. Fritsche, and R. N. Jones. 2004. Initial results from a longitudinal international surveillance programme for anidulafungin (2003). J. Antimicrob. Chemother. 54:1051-1056.[Abstract/Free Full Text]
    11. 11
  11. Moore, C. B., K. L. Oakley, and D. W. Denning. 2001. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin. Microbiol. Infect. 7:11-16.[CrossRef]
    12. 12
  12. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard—2nd edition. NCCLS document M27-A2. NCCLS, Wayne, Pa.
    13. 13
  13. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.[Abstract/Free Full Text]
    14. 14
  14. Pfaller, M. A., S. A. Messer, and S. Coffman. 1997. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:763-766.[Abstract]
    15. 15
  15. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.[CrossRef][Medline]
    16. 16
  16. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates. J. Clin. Microbiol. 42:3117-3119.[Abstract/Free Full Text]
    17. 17
  17. Quindos, G., A. J. Carrillo-Munoz, M. P. Arevalo, J. Salgado, R. Alonso-Vargas, J. M. Rodrigo, M. T. Ruesga, A. Valverde, J. Peman, E. Canton, E. Martin-Mazuelos, and J. Ponton. 2000. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents. Chemotherapy 46:395-401.[CrossRef][Medline]
    18. 18
  18. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.[CrossRef][Medline]
    19. 19
  19. Uzun, O., S. Kocagoz, Y. Cetinkaya, S. Arikan, and S. Unal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157.[Abstract]

Antimicrobial Agents and Chemotherapy, November 2005, p. 4795-4797, Vol. 49, No. 11
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.11.4795-4797.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Garcia-Effron, G., Park, S., Perlin, D. S. (2009). Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints. Antimicrob. Agents Chemother. 53: 112-122 [Abstract] [Full Text]  
  • Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., Hou, J. (2008). In Vivo Pharmacodynamic Characterization of Anidulafungin in a Neutropenic Murine Candidiasis Model. Antimicrob. Agents Chemother. 52: 539-550 [Abstract] [Full Text]  
  • Zeng, X., Kong, F., Halliday, C., Chen, S., Lau, A., Playford, G., Sorrell, T. C. (2007). Reverse Line Blot Hybridization Assay for Identification of Medically Important Fungi from Culture and Clinical Specimens. J. Clin. Microbiol. 45: 2872-2880 [Abstract] [Full Text]  
  • Gumbo, T., Drusano, G. L., Liu, W., Kulawy, R. W., Fregeau, C., Hsu, V., Louie, A. (2007). Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia. Antimicrob. Agents Chemother. 51: 968-974 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J. (2007). Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem. Clin. Microbiol. Rev. 20: 133-163 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Goldstein, B. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pfaller, M. A.
Right arrow Articles by Goldstein, B. P.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»